Livzon Pharma (01513) announced that as of July 31, 2024, the company repurchased a total of 4.8942 million A shares, accounting for 0.53% of the total share capital of the company, through centralized bidding trading...
According to a statement released by Livzon Pharma (01513), as of July 31, 2024, the company repurchased a total of 4.8942 million A shares through centralized bidding trading, accounting for 0.53% of the company's total share capital. The highest purchase price was RMB 36.80 per share, the lowest was RMB 32.95 per share, and the total amount of funds used for the repurchase was RMB 0.172 billion yuan (excluding transaction costs). The buyback is in compliance with the company's established buyback program.